Pillstats
Rx only · Injection, Solution · Subcutaneous

Sarilumab

Brands: Kevzara · Sarilumab

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US4 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCL04AC14
RxCUI (US)1923319
US makers1 labelers
Packages8
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$596.36$1192.72$1789.08$2385.44Jan 2026Jun 2026Jul 2026
$2068.856
Latest avg · Jul 22, 2026
-0%
Since Jan 1, 2026
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

9721.9K2.9K3.9K2025 Q12025 Q22025 Q32025 Q42026 Q1
3.0K
Rx · 2026 Q1
6.9K
Units dispensed
-5%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Sanofi-Aventis U.S. LLCunknown8SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.